ProjectStudie CDRB436F2302T - EADO ADAPT-BIO
Basic data
Title:
Studie CDRB436F2302T - EADO ADAPT-BIO
Duration:
18/12/2018 to 31/12/2026
Abstract / short description:
Clinical trial known as Adjuvant dabrafenib plus trametinib in high risk stage II BRAF mutated melanoma. A randomized double blind placebo controlled phase III trial with biomarker based patient selection
Keywords:
melanoma
Melanom
biomarker
Biomarker
BRAF
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Basel, Switzerland